Open AccessUrticaria is not a sentence. The clinical cases
Author(s) -
И В Данилычева,
A E Shulzhenko,
N G Bondarenko
Publication year - 2016
Publication title -
rossijskij allergologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2686-682X
pISSN - 1810-8830
DOI - 10.36691/rja374
Subject(s) - omalizumab , medicine , refractory (planetary science) , immunoglobulin e , monoclonal antibody , chronic urticaria , dermatology , monoclonal , immunology , antibody , biology , astrobiology
Omalizumab - monoclonal therapeutic antibody to human IgE, is effectively used for the treatment of patients with chronic spontaneous urticaria (HSC), refractory to 4 times increased doses of antihistamines. The article describes two cases of effective treatment of patients (HSC) with omalizumab (Xolair® «Novartis Pharma» LLC) after a long period of unsuccessful therapy with H1-antihistamines, leukotriene receptor antagonists, and corticosteroids.